RxDoctor Payments Data

Aubrey Moss

Psychiatric/Mental Health · Murfreesboro, TNNPI 1144004185

Payments from drug & device makers

$835in general payments, 2019–2025

Across 28 payments — averaging $29.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$209
  • Teva Pharmaceuticals USA, Inc.$186
  • E.r. Squibb & Sons, L.L.C.$93
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • Alkermes, Inc.$58
  • Neurocrine Biosciences, Inc.$52
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835 in reported general payments places this provider in the 50th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,373
Medicare patients
54
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$135,678
VraylarCariprazine Hcl78$120,196
CaplytaLumateperone Tosylate18$29,564
FetzimaLevomilnacipran Hcl35$17,108
RexultiBrexpiprazole11$16,350
FanaptIloperidone16$15,701
TrintellixVortioxetine Hydrobromide23$11,046
Ziprasidone Hcl65$7,481
Aripiprazole94$7,143
ProzacFluoxetine Hcl11$5,977
Quetiapine Fumarate251$5,400
Venlafaxine Hcl ErVenlafaxine Hcl39$5,099
Divalproex Sodium ErDivalproex Sodium69$4,958
Vilazodone Hcl31$4,893
VyvanseLisdexamfetamine Dimesylate12$4,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$209$137,304113 claims
Teva Pharmaceuticals USA, Inc.Austedo$186$135,67820 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$91$29,56418 claims
Otsuka America Pharmaceutical, Inc.Rexulti$37$16,35011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →